Inhibrx reports initial Phase I Ewing sarcoma trial data

Inhibrx has reported initial findings from the Phase I clinical trial of INBRX-109 plus Irinotecan and Temozolomide (IRI/TMZ) to treat advanced or metastatic, unresectable Ewing sarcoma (EWS).

The trial analysed the safety and efficacy of the combination treatment for EWS, a rare, aggressive tumour that occurs in adults and children.